open access

Vol 25, No 5 (2018)
Original articles — Clinical cardiology
Published online: 2017-12-14
Get Citation

Short- and long-term effects of hemodialysis on platelet and monocyte activity markers of atherosclerosis in patients with end-stage renal disease

Urs Benck, Ksenija Stach, Susanne Jung, Bernhard K. Krämer, Thorsten Kälsch, Anna-Isabelle Kälsch
DOI: 10.5603/CJ.a2017.0152
·
Pubmed: 29240958
·
Cardiol J 2018;25(5):595-600.

open access

Vol 25, No 5 (2018)
Original articles — Clinical cardiology
Published online: 2017-12-14

Abstract

Background: In hemodialysis (HD) patients cardiovascular events represent the predominant cause of mortality. Since platelet and monocyte activity markers play an important role in cardiovascular mortality, this study assessed the influence of HD on these markers.

Methods: Forty one HD patients (25 male, 16 female) were included. Blood samples were obtained before and after a single HD session at baseline and again after an elapsed period of 114 ± 21 days (91–175 days) on maintenance hemodialysis. Surface expression of CD40L and CD62P on platelets, tissue factor binding on monocytes and platelet-monocyte aggregates were measured by flow cytometry. Plasma levels of monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFa) and soluble CD40L were analyzed by enzyme linked immunosorbent assay.

Results: Tissue factor on monocytes was significantly increased after a single HD session at baseline (p = 0.041), whereas platelet-monocyte aggregates, the expression of CD40L and CD62P on platelets did not change significantly. After a mean of 114 ± 21 days of HD therapy, tissue factor on monocytes (p < 0.0001), platelet-monocytes aggregates (p < 0.0001), plasma levels of MCP-1 (p = 0.012) and TNFa (p = 0.046) were significantly decreased compared to baseline values. In contrast, platelet surface expression of CD40L and CD62P as well as plasma levels of sCD40L and IL-6 were not attenuated significantly. There was no significant correlation detected between the markers examined and the cumulative time on hemodialysis.

Conclusions: Platelet and monocyte activity markers assessed in this study do not appear to be significantly increased by HD therapy. Therefore, these markers probably cannot be accountable for increased cardiovascular mortality in chronic HD patients.

Abstract

Background: In hemodialysis (HD) patients cardiovascular events represent the predominant cause of mortality. Since platelet and monocyte activity markers play an important role in cardiovascular mortality, this study assessed the influence of HD on these markers.

Methods: Forty one HD patients (25 male, 16 female) were included. Blood samples were obtained before and after a single HD session at baseline and again after an elapsed period of 114 ± 21 days (91–175 days) on maintenance hemodialysis. Surface expression of CD40L and CD62P on platelets, tissue factor binding on monocytes and platelet-monocyte aggregates were measured by flow cytometry. Plasma levels of monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFa) and soluble CD40L were analyzed by enzyme linked immunosorbent assay.

Results: Tissue factor on monocytes was significantly increased after a single HD session at baseline (p = 0.041), whereas platelet-monocyte aggregates, the expression of CD40L and CD62P on platelets did not change significantly. After a mean of 114 ± 21 days of HD therapy, tissue factor on monocytes (p < 0.0001), platelet-monocytes aggregates (p < 0.0001), plasma levels of MCP-1 (p = 0.012) and TNFa (p = 0.046) were significantly decreased compared to baseline values. In contrast, platelet surface expression of CD40L and CD62P as well as plasma levels of sCD40L and IL-6 were not attenuated significantly. There was no significant correlation detected between the markers examined and the cumulative time on hemodialysis.

Conclusions: Platelet and monocyte activity markers assessed in this study do not appear to be significantly increased by HD therapy. Therefore, these markers probably cannot be accountable for increased cardiovascular mortality in chronic HD patients.

Get Citation

Keywords

platelets; monocytes; hemodialysis; atherosclerosis

About this article
Title

Short- and long-term effects of hemodialysis on platelet and monocyte activity markers of atherosclerosis in patients with end-stage renal disease

Journal

Cardiology Journal

Issue

Vol 25, No 5 (2018)

Pages

595-600

Published online

2017-12-14

DOI

10.5603/CJ.a2017.0152

Pubmed

29240958

Bibliographic record

Cardiol J 2018;25(5):595-600.

Keywords

platelets
monocytes
hemodialysis
atherosclerosis

Authors

Urs Benck
Ksenija Stach
Susanne Jung
Bernhard K. Krämer
Thorsten Kälsch
Anna-Isabelle Kälsch

References (23)
  1. Eknoyan G, Beck GJ, Cheung AK, et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347(25): 2010–2019.
  2. Paniagua R, Amato D, Vonesh E, et al. Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002; 13(5): 1307–1320.
  3. Wang AYM, Lam CWK, Wang M, et al. Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: a prospective cohort study. Am J Nephrol. 2008; 28(4): 647–653.
  4. Sagripanti A, Barsotti G. Bleeding and Thrombosis in Chronic Uremia. Nephron. 1997; 75(2): 125–139.
  5. Evans EP, Branch RA, Bloom AL. A clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol. 1972; 25(9): 745–753.
  6. Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation. 1998; 98(12): 1164–1171.
  7. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004; 30(5): 579–589.
  8. Schoorl M, Schoorl M, Nubé MJ, et al. Platelet depletion, platelet activation and coagulation during treatment with hemodialysis. Scand J Clin Lab Invest. 2011; 71(3): 240–247.
  9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105(9): 1135–1143.
  10. Gawaz M, Brand K, Dickfeld T, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis. 2000; 148(1): 75–85.
  11. Frenette PS, Johnson RC, Hynes RO, et al. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A. 1995; 92(16): 7450–7454.
  12. Locatelli F, Vecchio LD, Manzoni C. Morbidity and Mortality on Maintenance Haemodialysis. Nephron. 1998; 80(4): 380–400.
  13. May AE, Kälsch T, Massberg S, et al. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation. 2002; 106(16): 2111–2117.
  14. Yorioka N, Taniguchi Y, Yamashita K, et al. Tissue factor and tissue factor pathway inhibitor in hemodialysis patients. Int J Artif Organs. 1998; 21(11): 699–701.
  15. Pawlak K, Pawlak D, Mysliwiec M. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. Thromb Res. 2007; 120(6): 871–876.
  16. Al-Saady NM, Leatham EW, Gupta S, et al. Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. Heart. 1999; 81(2): 134–140.
  17. Kappelmayer J, Bernabei A, Edmunds LH, et al. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res. 1993; 72(5): 1075–1081.
  18. Kobayashi S, Miyamoto M, Kurumatani H, et al. Increased leukocyte aggregates are associated with atherosclerosis in patients with hemodialysis. Hemodial Int. 2009; 13(3): 286–292.
  19. Gawaz MP, Mujais SK, Schmidt B, et al. Platelet-leukocyte aggregates during hemodialysis: effect of membrane type. Artif Organs. 1999; 23(1): 29–36.
  20. Naumnik B, Koc-Żórawska E, Myśliwiec M. Over-dialysis plasma RANTES increase depends on heparin dose and cardiovascular disease status. Adv Med Sci. 2013; 58(2): 311–319.
  21. Schwabe RF, Engelmann H, Hess S, et al. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Immunol. 1999; 117(1): 153–158.
  22. Rusu C, Racasan S, Moldovan D, et al. Soluble CD40 ligand in haemodialysis patients: survival impact and cardiovascular prognostic role. Biomarkers. 2017; 22(3-4): 232–238.
  23. Stach K, Karb S, Akin I, Borggrefe M, Krämer B, Kälsch T, Kälsch A.-I: Elevation of Platelet and Monocyte Activity Markers of Atherosclerosis in Haemodialysis Patients Compared to Peritoneal Dialysis Patients. Mediators of inflammation 2017. https://doi.org/10.1155/2017/8506072.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl